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Message
The incidence of oesophageal adenocarcinoma 
(EAC) is steeply rising. Early lesion detection is a 
critical factor for improving disease prognosis. We 
developed and investigated wide-field near-infrared 
fluorescence molecular endoscopy (NIR-FME), 
using systemic and topical administration of a fluo-
rescence-labelled antibody against vascular endo-
thelial growth factor (VEGFA). Fourteen patients 
with Barrett’s oesophagus (BE) underwent endo-
scopic mucosal resection (EMR) combined with 
NIR-MFE. From a total of 20 confirmed aber-
rant lesions identified with NIR-FME, 4 lesions 
were missed by high-definition (HD) narrowband 
imaging (NBI) and white-light endoscopy (WLE). 
This overall 25% detection enhancement advocates 
NIR-FME as a promising ‘red-flag’ technique for 
improving early oesophageal lesion detection.  Clin-
icalTrials. gov ID NCT02129933.  
In More detaIl
Worldwide, >450 000 people are diagnosed with 
oesophageal cancer each year. In the western world, 
at least 80% of these cancers concern EAC.1–4 Late-
stage disease detection challenges the efficacy of 
therapies, resulting in 400 000 deaths each year. 
Therefore, there is a pressing need for new endo-
scopic techniques that enable early EAC detection. 
Endoscopic imaging of targeted fluorescent agents 
directed against cancer-specific cellular and subcel-
lular moieties, that is, fluorescence molecular endos-
copy (FME), has been heralded as a novel method 
for oesophageal dysplasia and cancer detection.5 
FME enables surface and subsurface visualisation of 
cancer-specific pathophysiology, going beyond the 
surface-only morphology and tissue discolourations 
visible with HD-WLE.6–10
In this study, we investigated for the first time real-
time NIR-FME of EAC and dysplasia. A pilot study 
in patients with BE was based on a novel custom-
built NIR fluorescence endoscope, paired to a 
HD-WL clinical scope (online supplementary figure 
1) and employed the anti-VEGFA antibody bevaci-
zumab, labelled with the NIR-fluorescent 800CW. 
The potential of VEGFA as an early discriminating 
target in BE was first confirmed by immunohisto-
chemistry, demonstrating that all dysplastic tissues 
expressed VEGFA (online supplementary figure 2).
The study furthermore compared systemic versus 
topical tracer administration during clinical inspec-
tion of the oesophagus in 14 patients with BE, 
scheduled to undergo an EMR of previously diag-
nosed lesions (figure 1A). Five patients received 
an intravenous bolus of bevacizumab 800CW, 
2 days prior to the NIR-FME procedure (4.5 mg, 
bolus injection). The other nine patients received 
topical administration of the tracer, by spraying 
bevacizumab 800CW on the luminal surface 
(100 µg/mL per cm BE) immediately prior to 
wide-field NIR-FME. The online supplemen-
tary table 1 summarises study subjects and lesion 
characteristics.
In the systemic tracer administration subgroup, 
four out of five EAC lesions were well identified 
by wide-field NIR-FME inspection (figure 1B). The 
fifth lesion had its origin in the gastric cardia and 
was only visible in endoscopic U-turn. Due to the 
bending restrictions of the current fibre bundle, 
this lesion was not accessible for the custom-built 
NIR-FME endoscope employed in the study. Never-
theless, this fifth lesion demontrated high fluores-
cent tracer uptake ex vivo (online supplementary 
figure 3). In the topical tracer group, NIR-FME 
visualised all (12/12) dysplastic and neoplastic 
lesions, exactly matching the contour of the lesion 
during HD-WLE inspection, including a carcino-
matous area that was only identified by random 
biopsies (figure 1C; total of 9 patients: 1/9 no 
focal lesion on HD-WLE/NBI inspection, 5/9 one 
focal lesion and 3/9 patients two focal lesions). In 
addition, topical tracer-based NIR-FME identified 
four additional dysplastic lesions, which were not 
identified by HD-WLE and NBI inspection (+33%, 
figure 1D). Moreover, the topical administration 
led to a slightly higher in vivo tumour-to-back-
ground ratio (TBR) of 4.30±0.41, compared with 
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CoMMents
The known limitations of clinically available endoscopes initi-
ated a search for novel imaging techniques that allow improved 
detection of early oesophageal lesions. FME is heralded as a 
highly promising method for detecting dysplastic and neoplastic 
lesions. To date, three studies—one ex vivo study and two clin-
ical trials—have been reported on FME in EAC5 11 12; however, 
none of these studies showed real-time wide-field inspection of 
the oesophageal lumen. Compared with previous studies, the 
NIR-FME technique offers three advantages. First, the system 
design enables concurrent use of HD-WLE and sensitive func-
tional fluorescence detection of lesions. Second, NIR-FME offers 
a ‘red-flag’ surveillance method that inspects at least four orders 
of magnitude higher fields of view compared with confocal 
laser endomicroscopy, an ability that can be further exploited 
to guide biopsy. Moreover, the switch from visible wavelengths 
in previous studies5 11 12 to the NIR leads to fluorescence detec-
tion with superior sensitivity, allowing for the first time real-
time in vivo WLE and concurrent FME imaging. Finally, NIR 
wavelengths are less subjected to interference by haemoglobin 
absorption, autofluorescence signals and tissue scattering.13
The endoscopic fluorescence images, concurrently recorded 
with HD-WLE in vivo, matched the focal areas as defined with 
HD-WLE. In addition, ex vivo fluorescence imaging precisely 
Figure 1 Real-time VEGFA-targeted NIR-FME. (A) Schematic overview and timeline of the two NIR-FME approaches (n=14). (B) Examples of the 
systemic tracer based, and (C) the topical tracer results, summarising that all lesions could be visualised with NIR-FME, including one EAC area which 
was not visible during HD inspection (displayed in C—first row). (D) Additionally identified dysplastic areas during NIR-FME, which were missed 
during HD-NBI inspection. All fluorescence signals presented here are uncorrected; overlay images display the high intensities only. EAC, oesophageal 
adenocarcinoma; HD, high-definition; HGD, high-grade dysplasia; LGD, low-grade dysplasia; NIR-FME, near-infrared fluorescence molecular 
endoscopy; NBI, narrow-band imaging; VEGFA, antibody against vascular endothelial growth factor.
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matched the histology findings (figure 2A; details online). The 
areas that exhibited increased fluorescence—including the areas 
that were not identified as dysplastic by HD-WLE—were identi-
fied as aberrant by histopathology (true positives; figure 1B–D). 
Random biopsies, which contained benign mucosal lining, did 
not exhibit fluorescence (true negatives). Moreover, we did not 
observe fluorescence at the submucosal layer or at the resection 
margin following EMR, which was confirmed by histopathology; 
all EMR procedures were radical (R0) resections, as evinced by 
follow-up endoscopy.
In addition, fluorescence signals recorded ex vivo were 
congruent with high intracellular VEGFA stainings (figure 2A). 
This finding is consistent with previous observations, linking 
(labelled)-bevacizumab uptake to areas of elevated VEGFA.14–16 
Furthermore, labelled bevacizumab has been shown trapped 
in the extracellular matrix, when bound to the large VEGFA 
isoforms that are attached to the cell surface.14 17 This reported 
high VEGFA expression in dysplastic and neoplastic areas can be 
explained by the role of VEGFA in neovascularisation and has 
been reported to be elevated already in BE dysplasia.17-22
Ex vivo assessment of the specimen obtained from the systemic 
tracer group showed significant differences in mean fluorescence 
intensity between the aberrant areas (EAC/high-grade dysplasia) 
and the benign mucosal lining, resulting in a favourable ex vivo 
TBR of 16.7 (figure 2B, P value <0.001). Furthermore, ex 
vivo NIR microscopy of the formalin-fixed and paraffin-em-
bedded slices confirmed the presence of NIR fluorescence in 
EAC areas (figure 2C), tumour stromal tissue and surrounding 
Figure 2 Ex vivo VEGFA and fluorescent signal analyses of study subjects. (A) Boxplot presenting IHC results (H-score: median, 10–90 percentile); 
a significant difference in VEGFA staining intensities is observed between the dysplastic and benign tissue sites (**P<0.0001). (B) Tukey boxplot 
presenting the MFIs observed (mean value in bold) (*P<0.05). (C) Fluorescence scan and 3D surface plot demonstrating that the tracer is located 
in the EAC area and (D) fluorescence microscopy of this same area showing NIR fluorescence within the stromal tissue, between the tumour ducts. 
(E) Fluorescence scan demonstrating that the tracer is located in tumour blood vessels and tumour ducts. EAC, oesophageal adenocarcinoma; 
EMR, endoscopic mucosal resection; HE, haematoxylin and eosin; HGD, high-grade dysplasia; IHC, immunohistochemistry; IM, intestinal metaplasia; 
MFI, mean fluorescence intensities; NIR, near-infrared; VEGFA, antibody against vascular endothelial growth factor.
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tumour blood vessels (figure 2D-E), while low fluorescence was 
seen at the margin containing normal Barrett lining. Likewise, 
macroscopic ex vivo imaging of the formalin-fixed specimens 
that received topical tracer administration exhibited NIR fluo-
rescence at dysplastic and EAC sites (online supplementary 
figure 5), though typically at lower intensity compared with the 
samples from the group receiving systemic administration due to 
agent washout during the fixation process.
We observed adverse events in 4/14 patients, all known 
complications of the EMR procedure: bleeding (n=2), nausea/
headache (n=1) and fever (n=1). Most likely these events are 
not tracer-related as only 1%–1.5% of the therapeutic bevaci-
zumab dose was used (4.5 mg vs 5 mg/kg). Our study has several 
limitations. First, our NIR-FME system uses a sensitive fibre 
bundle for fluorescence imaging, but an integrated NIR imaging 
system in a standard HD endoscope would most likely simplify 
the procedure. Second, our patient sample is small and powered 
as phase I study for safety, therefore, a randomised phase II or 
III trial is required to verify the additive role of NIR-FME in BE 
surveillance.
In conclusion, this work demonstrates that concurrent use of 
VEGFA-guided NIR-FME and HD-WLE, following topical or 
systemic tracer administration, can be used to detect dysplastic 
and early EAC lesions in patients with BE. Our in vivo results 
show that even flat and difficult to distinguish lesions were iden-
tifiable with NIR-FME. Moreover, the topical tracer approach 
was able to improve early lesion detection by ~33% compared 
with HD-WL/NBI endoscopy.
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